Ubs Group Ag Sci Sparc Ltd. Transaction History

Ubs Group Ag

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.45 - $1.07 $5,239 - $12,458	11,643 Added 331.9%	15,151 $6,000
Q4 2022 Feb 08, 2023	SELL	$0.73 - $28.08 $15,914 - $612,144	-21,800 Reduced 86.14%	3,508 $2,000
Q3 2022 Nov 10, 2022	BUY	$0.72 - $21.81 $14,338 - $434,346	19,915 Added 369.27%	25,308 $21,000
Q2 2022 Aug 10, 2022	SELL	$1.89 - $3.68 $6,911 - $13,457	-3,657 Reduced 40.41%	5,393 $11,000
Q1 2022 May 16, 2022	BUY	$3.5 - $6.73 $31,675 - $60,906	9,050 New	9,050 $35,000

Ticker SPRC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 3,526,740
Market Cap $1.52M
Description
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum ...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.